Protalix BioTherapeutics resolves stockholder class action; pays $160k fees

Protalix BioTherapeutics, Inc.

Plaintiff Kevin Mathew Thomas filed suit on March 10, 2025, challenging certain bylaws provisions under Delaware law.
On May 8, 2025, the Board amended the challenged bylaws, rendering plaintiff's claims moot.
Company agreed to pay $160,000 in fees and expenses to plaintiff's counsel; no admission of wrongdoing.
Court entered dismissal with prejudice as to plaintiff on July 23, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.